• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].勘误：日本视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗后注射间隔时间的延长 [勘误]
Clin Ophthalmol. 2017 Apr 5;11:619. doi: 10.2147/OPTH.S136670. eCollection 2017.
2
Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion.在日本视网膜分支静脉阻塞继发黄斑水肿患者中，从雷珠单抗转换为阿柏西普治疗后延长注射间隔时间。
Clin Ophthalmol. 2017 Feb 22;11:403-408. doi: 10.2147/OPTH.S128651. eCollection 2017.
3
Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.阿柏西普对视网膜中央静脉阻塞继发的持续性黄斑水肿的影响。
J Fr Ophtalmol. 2018 Nov;41(9):809-813. doi: 10.1016/j.jfo.2018.01.024. Epub 2018 Oct 22.
4
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.在视网膜中央静脉阻塞中从雷珠单抗和/或贝伐单抗转换为阿柏西普治疗后的临床结局
Ophthalmic Res. 2015;54(3):150-6. doi: 10.1159/000439223. Epub 2015 Sep 29.
5
Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.阿柏西普和雷珠单抗“治疗并监测”方案用于非缺血性视网膜分支静脉阻塞继发黄斑水肿的疗效
Int Ophthalmol. 2019 Jan;39(1):145-153. doi: 10.1007/s10792-017-0798-6. Epub 2017 Dec 22.
6
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.阿柏西普用于视网膜分支静脉阻塞的二线治疗：从贝伐单抗/雷珠单抗换药12个月后的临床结果——一项前瞻性研究
Int J Retina Vitreous. 2016 Aug 23;2:20. doi: 10.1186/s40942-016-0045-8. eCollection 2016.
7
The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.在缺血性中央静脉阻塞继发黄斑水肿的难治性病例中，将雷珠单抗换用阿柏西普的效果。
Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22.
8
Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.雷珠单抗与阿柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的成本效益：英国医疗保健视角
Adv Ther. 2016 Jan;33(1):116-28. doi: 10.1007/s12325-015-0279-0. Epub 2016 Jan 8.
9
Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.雷珠单抗治疗无效的视网膜中央静脉阻塞继发黄斑水肿患者改用阿柏西普治疗的效果
Int Ophthalmol. 2018 Feb;38(1):207-213. doi: 10.1007/s10792-017-0512-8. Epub 2017 Apr 12.
10
Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.雷珠单抗与阈下微脉冲激光治疗视网膜分支静脉阻塞继发黄斑水肿的比较。
Eur J Ophthalmol. 2018 Nov;28(6):690-696. doi: 10.1177/1120672117750056. Epub 2018 Apr 26.

勘误：日本视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗后注射间隔时间的延长 [勘误]

Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].

出版信息

Clin Ophthalmol. 2017 Apr 5;11:619. doi: 10.2147/OPTH.S136670. eCollection 2017.

DOI:10.2147/OPTH.S136670
PMID:28435211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5388265/
Abstract

[This corrects the article on p. 403 in vol. 11, PMID: 28260852.].

摘要

[这更正了第11卷第403页上的文章，PMID: 28260852。]